787583-71-5 Usage
General Description
The chemical [1,1'-Biphenyl]-4-carboxylic acid, 2'-[(1R)-1-[(2R)-3-[[2-(4-chloro-3-fluorophenyl)-1,1-dimethylethyl]amino]-2-hydroxypropoxy]ethyl]-3-methyl- is a complex compound that consists of a biphenyl carboxylic acid group and a substituted amine group. The compound features a 4-carboxylic acid moiety attached to a 2'-[(1R)-1-[(2R)-3-[[2-(4-chloro-3-fluorophenyl)-1,1-dimethylethyl]amino]-2-hydroxypropoxy]ethyl]-3-methyl- structure. The presence of a biphenyl group and a carboxylic acid functionality makes the compound relevant in the field of organic synthesis and medicinal chemistry. The substituted amine group also suggests potential pharmacological activity, warranting further investigation for its potential use in drug development and biological studies.
Check Digit Verification of cas no
The CAS Registry Mumber 787583-71-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 7,8,7,5,8 and 3 respectively; the second part has 2 digits, 7 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 787583-71:
(8*7)+(7*8)+(6*7)+(5*5)+(4*8)+(3*3)+(2*7)+(1*1)=235
235 % 10 = 5
So 787583-71-5 is a valid CAS Registry Number.
787583-71-5Relevant articles and documents
Discovery of a potent and short-acting oral calcilytic with a pulsatile secretion of parathyroid hormone
Shinagawa, Yuko,Inoue, Teruhiko,Katsushima, Takeo,Kiguchi, Toshihiro,Ikenogami, Taku,Ogawa, Naoki,Fukuda, Kenji,Hirata, Kazuyuki,Harada, Kazuhito,Takagi, Masaki,Nakagawa, Takashi,Kimura, Shuichi,Matsuo, Yushi,Maekawa, Mariko,Hayashi, Mikio,Soejima, Yuki,Takahashi, Mitsuru,Shindo, Masanori,Hashimoto, Hiromasa
, p. 238 - 242 (2011/04/26)
Short-acting oral calcilytics, calcium-sensing receptor (CaSR) antagonists, have been considered as alternatives for parathyroid hormone (PTH), an injectable bone anabolic drug used in the treatment of osteoporosis. Previously, we identified aminopropandi
CaSR antagonist
-
Page/Page column 42, (2010/02/10)
A compound represented by the following formula (1), a pharmaceutically acceptable salt thereof or an optically active form thereof: wherein each symbol is as defined in the specification. A compound having a calcium-sensing receptor antagonistic action, a pharmaceutical composition comprising the compound, particularly a calcium receptor antagonist and a therapeutic drug for osteoporosis are provided.
